Vikas Gupta on Recipharm Group’s ‘compelling proposition’ for the biologics market and its ‘big presence’ at BIO Boston
BPR: What is ReciBioPharm planning at BIO International Boston?
ReciBioPharm has a big presence at the upcoming BIO Boston conference, highlighting all its four business units: ReciBioPharm, Oral Solid Dosage, Sterile Fill & Finish, and Advanced Delivery Systems.
ReciBioPharm will be represented by both the commercial and the executive leadership team.
Our focus will be on introducing the newly-formed biologics business unit’s combined capabilities to potential business partners visiting the conference.
We are also holding a drinks reception celebrating the formation of ReciBioPharm.
BPR: Could you tell us about your recent appointment to head up ReciBioPharm and what you are focusing on?
My appointment came as we officially renamed our biologics division. With the recently acquired businesses fully integrated under the ReciBioPharm brand, I will be focused on leading the team to promote this full service offering to innovative biotechs looking to advance their therapies and bring their drug products to market.
Backed by the strength of the Recipharm Group, we offer a very compelling proposition for the biologics market.
BPR: What impact will the recent acquisitions of Vibalogics, GenIbet and Arranta have on ReciBioPharm and its growth?
The acquisitions have allowed us to expand our specialised CDMO capabilities from preclinical-to-clinical and commercial approval for new biological modalities encompassing technologies based on live viruses and viral vectors, recombinant proteins, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.
The acquisitions add over 500K square feet of state-of-the-art process development and commercial manufacturing space to Recipharm.
BPR: How is ReciBioPharm expanding its plasmid DNA manufacturing capacity to meet current demand?
Research applications for genetic vaccinations and gene therapies continue to rise. To meet demand from biotechs and CDMOs looking to develop cell and gene therapies and vaccines, we are bolstering our plasmid DNA manufacturing capabilities and capacity.
Scaling up plasmid manufacturing can be difficult, and we provide available capacity to not only onboard new projects quickly, but also respond flexibly to challenges.
Backed by the strength of the Recipharm Group, ReciBioPharm’s combined breadth of services and expertise, means that we are well placed to support an increase in demand for these specialist services.
